Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ocugen Inc (NQ: OCGN ) 1.750 -0.060 (-3.31%) Streaming Delayed Price Updated: 12:51 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ocugen Inc < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Dear OCGN Stock Fans, Mark Your Calendars for Feb. 21 February 20, 2024 Ocugen stock is rising higher on Tuesday as OCGN fans prepare for a Clinical Showcase tomorrow that could be a positive catalyst for shares. Via InvestorPlace Why Discover Financial Services Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket February 20, 2024 Shares of Discover Financial Services (NYSE: DFS) shares rose sharply in today’s pre-market trading. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 20, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday February 20, 2024 Pre-market stock movers are a hot topic on Tuesday morning as we start the day with a breakdown of all the latest stock market news! Via InvestorPlace Recap: Ocugen Q3 Earnings November 09, 2023 Via Benzinga Earnings Outlook For Ocugen November 08, 2023 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session February 16, 2024 Via Benzinga Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024 February 14, 2024 From Ocugen Via GlobeNewswire Ocugen to Present at Pharma Market Research Conference January 31, 2024 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board January 16, 2024 From Ocugen Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's After-Market Session January 02, 2024 Via Benzinga Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design December 21, 2023 From Ocugen Via GlobeNewswire Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations December 19, 2023 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration December 13, 2023 From Ocugen Via GlobeNewswire Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference November 29, 2023 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease November 10, 2023 From Ocugen Via GlobeNewswire Ocugen (OCGN) Q3 2023 Earnings Call Transcript November 09, 2023 OCGN earnings call for the period ending September 30, 2023. Via The Motley Fool Topics Earnings Exposures Financial Ocugen Provides Business Update with Third Quarter 2023 Financial Results November 09, 2023 From Ocugen Via GlobeNewswire Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit November 07, 2023 From Ocugen Via GlobeNewswire Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results November 02, 2023 From Ocugen Via GlobeNewswire Why Is Archer Aviation (ACHR) Stock Moving Today? October 10, 2023 Archer Aviation stock is on a wild ride Tuesday morning after a short report targeting one of its rivals sent ACHR shares down this morning. Via InvestorPlace Why Is Ocugen (OCGN) Stock Up 5% Today? October 10, 2023 Ocugen stock is rising higher on Tuesday thanks to OCGN investors celebrating news of a new clinical trial for its Covid-19 vaccine. Via InvestorPlace Exposures COVID-19 Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials October 10, 2023 From Ocugen Via GlobeNewswire Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa October 04, 2023 From Ocugen Via GlobeNewswire Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference September 29, 2023 From Ocugen Via GlobeNewswire Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference September 27, 2023 From Ocugen Via GlobeNewswire Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board September 21, 2023 From Ocugen Via GlobeNewswire Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023 September 20, 2023 From Ocugen Via GlobeNewswire Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) September 13, 2023 From Ocugen Via GlobeNewswire Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023 September 12, 2023 Company to share updated results from ongoing Phase 1/2 trial of OCU400 for the treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis From Ocugen Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.